- Home
- RIGL vs VSTA Comparison
RIGL vs VSTA Comparison
Compare RIGL & VSTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RIGL
- VSTA
- Stock Information
- Founded
- RIGL 1996
- VSTA 1966
- Country
- RIGL United States
- VSTA Brazil
- Employees
- RIGL N/A
- VSTA N/A
- Industry
- RIGL Biotechnology: Pharmaceutical Preparations
- VSTA Other Consumer Services
- Sector
- RIGL Health Care
- VSTA Real Estate
- Exchange
- RIGL Nasdaq
- VSTA Nasdaq
- Market Cap
- RIGL 335.5M
- VSTA 332.9M
- IPO Year
- RIGL 2000
- VSTA 2020
- Fundamental
- Price
- RIGL $38.85
- VSTA $4.28
- Analyst Decision
- RIGL Buy
- VSTA Sell
- Analyst Count
- RIGL 5
- VSTA 1
- Target Price
- RIGL $38.20
- VSTA N/A
- AVG Volume (30 Days)
- RIGL 995.6K
- VSTA 14.1K
- Earning Date
- RIGL 08-05-2025
- VSTA 08-06-2025
- Dividend Yield
- RIGL N/A
- VSTA N/A
- EPS Growth
- RIGL N/A
- VSTA N/A
- EPS
- RIGL 5.43
- VSTA 1.09
- Revenue
- RIGL $267,921,000.00
- VSTA $313,466,268.00
- Revenue This Year
- RIGL $59.93
- VSTA $12.29
- Revenue Next Year
- RIGL N/A
- VSTA $11.91
- P/E Ratio
- RIGL $7.15
- VSTA $3.94
- Revenue Growth
- RIGL 105.62
- VSTA 8.99
- 52 Week Low
- RIGL $12.66
- VSTA $1.60
- 52 Week High
- RIGL $43.72
- VSTA $5.49
- Technical
- Relative Strength Index (RSI)
- RIGL 68.57
- VSTA 56.69
- Support Level
- RIGL $39.00
- VSTA $3.78
- Resistance Level
- RIGL $42.08
- VSTA $4.38
- Average True Range (ATR)
- RIGL 2.32
- VSTA 0.18
- MACD
- RIGL -0.37
- VSTA 0.00
- Stochastic Oscillator
- RIGL 53.26
- VSTA 83.33
About RIGL Rigel Pharmaceuticals Inc.
Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's primary drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility for developing and marketing the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.
About VSTA Vasta Platform Limited
Vasta Platform Ltd operates as an education company in Brazil, engaged in providing end-to-end educational and digital solutions that cater to all needs of private schools operating in the K-12 educational segment. Its business segments are Content and EdTech Platform, and Digital Platform. The Content and EdTech platform derives its results from educational content solutions through digital and printed content, including textbooks, learning systems and other complementary educational services. The Digital Platform enables private schools to aggregate multiple learning strategies and helps them to focus on education through the Business' physical and digital e-commerce platform and other digital services.